ABOUT 1st_EBOIF
> ATTENDEES​
> INVESTORS​
> PRESENTERS​
> EXHIBITORS​
> SPONSORS​
> SUPPORTERS​

20-minute presenters

Aphaia Pharma AG

Aphaia Pharma is a clinical-stage biopharma company harnessing precision-targeted drug formulations to restore endogenous endocrine and neuroendocrine balance for the treatment of obesity and associated metabolic diseases.​

www.aphaiapharma.com

CRS Mannheim

CRS is a leading full-service early phase Contract Research Organization (CRO) with two state-of-the-art research units in Germany. We excel in innovative solutions for early clinical development, from First-in-Human studies to Proof-of-Concept trials in patients.

We specialize in obesity, metabolic and cardiovascular disorders, and clinical trials involving renal and hepatic impaired patients. Leveraging our deep knowledge, we provide expert guidance to navigate the complexities of drug development.

Our extensive expertise makes us an ideal partner for biopharmaceutical companies, offering strategic and tactical project-related outsourcing partnerships.

www.crs-group.de

Rejuvenate Biomed NV

Rejuvenate Biomed is an AI-enabled, clinical-stage biotech company decoding the biology of aging to develop safe, synergistic combination therapeutics that holistically address the root causes of age-related diseases.  Its lead Phase 2 asset, RJx-01, has already demonstrated significant potential in treating sarcopenia. By targeting multiple disease pathways simultaneously, the company aims to provide more effective treatments that can alter the course of disease. Utilizing two clinically validated proprietary drug discovery platforms, AI-enabled in silico CombinAgeTM and in vivo CelegAgeTM, Rejuvenate Biomed has generated a robust pipeline of five unique combination drugs targeting different age-related diseases. These conditions range from neuromuscular, musculoskeletal, metabolic, neurodegenerative and immunology related indications. The company’s disease agnostic drug discovery platforms continue to provide insight by uncovering hidden patterns in biomedical graphs into future therapeutics, driving pipeline growth and potential partnerships. Rejuvenate Biomed is dedicated to promoting healthy aging.​

www.rejuvenatebiomed.com

Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical: Revolutionizing Inflammatory and Metabolic Care

Sen-Jam Pharmaceutical is pioneering a revolutionary approach to inflammatory and metabolic disorders with our proprietary PAIR (Pleiotropic Anti-Inflammatory Regulators) technology. By working with the body’s innate wisdom, our precision anti-inflammatories modulate inflammation at its source, addressing systemic risks linked to chronic conditions like obesity, metabolic dysfunction, and autoimmune diseases—all without suppressing the immune system. We are leading the next evolution in healthcare, delivering innovative treatments that enhance vitality, extend health spans, and redefine how the world heals.

What Problem Are We Solving?
Chronic inflammation is a silent driver of countless diseases, from metabolic disorders like obesity and MASLD to autoimmune and everyday health challenges. Yet, current treatments often suppress the immune system, creating new risks. The world needs a smarter, safer way to address inflammation and metabolic dysfunction at their core without compromising overall health. Sen-Jam Pharmaceutical’s breakthrough PAIR technology is designed to solve this urgent problem, offering precision anti-inflammatory and metabolic solutions that preserve vitality, support weight management, enhance productivity, and improve lives.

What’s Our Unfair Advantage?
Sen-Jam Pharmaceutical’s “unfair advantage” lies in the exceptional caliber of our team and the groundbreaking potential of our proprietary PAIR technology. Our scientific advisors, with decades of experience at world-renowned institutions like the Mayo Clinic, Boston Medical Center, Harvard School of Public Health are Ivy League-published experts solving the world’s toughest health challenges. This unparalleled expertise, combined with our precision-driven approach to inflammatory and metabolic care, positions Sen-Jam to disrupt the market and emerge as a transformative unicorn in healthcare.

www.sen-jam.com

Skye Bioscience, Inc.
[NASDAQ:SKYE]

Skye is unlocking new therapeutic pathways for obesity and other metabolic conditions through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutic candidates with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). Skye expects to report 26-week data from this study in late Q3/early Q4.

www.skyebioscience.com

VIVUS

We are a global pharmaceutical and biotechnology company.  We have three commercial products in weight loss, pancreatic enzyme replacement therapy and ED.  We have development products in endocrinology, pulmonary arterial hypertension and oncology.​

www.vivus.com

10-minute presenters

Clinical Ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with eCOA, eDC, Digital Biomarkers and patient engagement tools (telehealth, eConsent, eRetention), drive the industry standard for precision data and usher in a new generation of clinical trials.​

www.clinicalink.com/

Rising Stars Session

Amaro Therapeutics, Inc.

Amaro Therapeutics is a preclinical platform company harnessing the extra‐oral bitter taste receptor (TAS2R) system—with an emphasis on human bitter taste receptor 1 (TAS2R1)—to develop novel small‐molecule therapeutics for metabolic diseases and diseases of aging. Although bitter taste receptors have been historically viewed as mediators of oral aversion, our thinking and emerging data suggest their primary function is nutrient‐sensing and further, the TAS2Rs system may be an endogenous system of deleterious cell clearance (i.e., cancer cells, senescent cells).  Ubiquitously expressed, TAS2R have demonstrated a clear immune-metabolic role in preclinical and clinical studies.  By targeting TAS2R1 agonism, Amaro hopes to restore healthy homeostasis by modulating metabolic pathways while simultaneously attenuating cellular senescence — all within a single therapeutic paradigm.​

www.amarotx.com

Cantoni Therapeutics BV

Cantoni Therapeutics is a private pharmaceutical company based in Leiden, the Netherlands dedicated to the discovery, development and commercialization of best-in-class small molecule inhibitors towards Nicotinamide N-methyltransferase, NNMT, a promising and novel target for cardiometabolic disease, with obesity and its comorbidities selected as lead indication.​

www.cantonitx.nl

Lipotype GmbH

Lipotype is the leading lipidomics provider for all scientists. Our mass spectrometry-based platform can be applied to all biological samples, and is completed with data visualization and statistical analyses. Order your lipidomics, send in your samples, and get your data in as little as two weeks.​

www.lipotype.com

PG40 GmbH

PG40 GmbH is a medical technology SME located in Leipzig, Germany. The company focuses on the development of real-time metabolic monitoring systems for use in spaceflight, clinical environments, and research. Our current project, diafyt, aims to build a wearable biosensor that tracks multiple metabolic markers—such as glucose, lactate, and cortisol—in real time. The technology is based on organic electrochemical transistors (OECTs), allowing for flexible, low-power operation. The system integrates AI algorithms to support data interpretation and predictive analysis. Together with partners from TU Dresden, DLR, and RISE in Sweden, the prototype is currently being validated under laboratory and spaceflight-simulated conditions. PG40 contributes expertise in sensor electronics, firmware development, and regulatory planning.

www.pg40.com

Primogene GmbH

Primogene is a biotechnology company developing biomanufacturing processes for the production of functional ingredients for human nutrition, health and personal care.

www.primogene.bio

virtual showcases

MetaVia Inc.
[​Nasdaq: MTVA]

MetaVia is a clinical-stage biotechnology company on a mission to transform the landscape of cardiometabolic diseases.

At the heart of MetaVia’s innovation is DA-1726, a novel 3:1 GLP-1/glucagon dual receptor agonist currently in clinical trials. Unlike existing GLP-1 therapies, which often suffer from poor long-term adherence due to gastrointestinal side effects, DA-1726 is designed to offer better tolerability and faster weight loss—critical improvements for sustaining long-term patient outcomes. In recent Phase 1 studies, DA-1726 achieved up to 6.3% weight loss in just four weeks without titration and delivered encouraging improvements in glycemic control and waist circumference.

The company is also advancing DA-1241, a first-in-class oral GPR119 agonist that recently demonstrated hepatoprotective and glucose-regulating effects in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). With both programs gaining clinical traction, MetaVia is positioning itself to address multiple high-value opportunities across obesity, MASH and type 2 diabetes.

www.metaviatx.com